Despite major advances in prevention and treatment of the ancient scourge tuberculosis in the past century, this disease remains a global tragedy with enormous public health and economic implications. Tuberculosis accounts for about 7% of all deaths in developing countries and 26% of avoidable adult deaths (2) . The World Health Organization estimates that 8 million new cases and 3 million deaths worldwide result each year from tuberculosis and has projected that 30 million people will die from this disease in the next decade (36) . Confounding these bleak statistics has been the emergence of the often fatal multiple-drug-resistant tuberculosis. Since multiple-drug-resistant tuberculosis bacilli are unsusceptible to most current antituberculosis medications, disease management of individual patients is difficult, and consequently, their infectiousness is prolonged. Therefore, multiple-drug-resistant tuberculosis has limited the effectiveness of tuberculosis control programs by complicating both treatment and prevention protocols (5, 7, 8) .
The continuing global threat of tuberculosis has emphasized the urgent need to design more effective diagnostic procedures and to develop improved antituberculosis therapies. The molecular definition of antituberculosis drug targets and resistance mechanisms should facilitate the rational development of improved diagnostics and antimycobacterial medications. Currently, the most effective and specific agent for the treatment of drug-susceptible Mycobacterium tuberculosis is isoniazid (INH). Although INH has been a central component of tuberculosis treatment protocols for several decades and drugresistant strains have been isolated since the 1950s, genetic markers associated with the resistant phenotype have only recently been elucidated. Zhang et al. have shown that the katG gene, which encodes the catalase-peroxidase enzyme, is absent from some INH-resistant M. tuberculosis strains and that transformation of the wild-type katG gene into katG-deleted mycobacterial strains restores INH susceptibility (37, 38) . Moreover, recent studies have demonstrated that a missense mutation in the inhA gene, which encodes an enoyl acyl reductase involved in mycolic acid biosynthesis, is associated with reduced susceptibility to INH in mycobacteria (1, 6) . Overexpression of the wild-type InhA protein also conferred increased INH resistance to transformed Mycobacterium smegmatis and Mycobacterium bovis.
In this study, we have extended the observations from other studies of the genetic markers of INH resistance to 26 clinical isolates of M. tuberculosis from the United States and South Korea. We have used single-stranded conformational polymorphism (SSCP), PCR, and nucleotide sequence analyses to detect mutations in the katG and inhA genes of these clinical isolates (21) . These findings have been correlated with results of catalase activity assays and antibiotic susceptibility testing. In addition, we have used site-directed mutagenesis techniques to evaluate the effect of the most frequently observed mutation in INH-resistant clinical isolates on both peroxidase activity and INH resistance.
MATERIALS AND METHODS
Characterization of M. tuberculosis clinical isolates. The bacterial isolates were obtained from the following locations: 6 from the Walter Reed Medical Center, Washington, D.C.; 1 from the National Institutes of Health Medical Center, Bethesda, Md.; and 19 from the Korean National Institute of Tuberculosis, Seoul, South Korea. The drug susceptibility profiles were determined by the absolute concentration method (32) . Resistance was defined as survival of the tubercle bacilli at the following drug concentrations: INH, 0.2 g/ml; streptomycin, 4 g/ml; rifampin, 32 g/ml; ethionamide, 20 g/ml; pyrazinamide, 100 g/ml; kanamycin, 50 g/ml; ethambutol, 3 g/ml. Whole-cell qualitative catalase assays were performed on each of the isolates. The catalase activities were recorded as negative (no O 2 release) or positive (visible O 2 bubbling).
Preparation of genomic mycobacterial DNA. The preparation of genomic DNA from mycobacterial strains has been described elsewhere (26) . Cell lysates from the Korean isolates which were utilized in PCR studies were prepared by extraction with chloroform (19) .
PCR-SSCP analyses. The protocols and reaction components utilized for the PCR-SSCP analyses have been described previously (19, 24) . In this study, the PCR-SSCP reaction mixtures were subjected to 40 cycles of PCR amplification (1 min at 95ЊC, 1 min at 60ЊC, 1 min at 72ЊC). The PCR-SSCP products were electrophoresed at 3 to 4 W for 16 to 18 h into a 0.5ϫ MDE gel by using a 0.6ϫ TBE buffer (60 mM Tris, 54 mM boric acid, 0.6 mM EDTA [pH 8.4] ). PCR products showing aberrant SSCP patterns were purified by using the Wizard purification procedure (Promega, Madison, Wis.) and then cloned by using the TA cloning system (Invitrogen, San Diego, Calif.). The cloned products were analyzed by using the BstI double-stranded DNA sequencing protocols (BioRad, Hercules, Calif.). At least two independent PCR clones were sequenced for each genetic analysis. To verify the presence of a mutational event, the nucleotide sequence of a PCR clone derived from a clinical isolate was compared with the DNA sequence of an M. tuberculosis strain H37Rv clone generated with the same PCR primer set. The specific primers utilized in this study have been listed previously (19) . The katG primers for both PCR and SSCP analyses were designed from the published M. tuberculosis katG gene sequence (12) . The inhA primers were generated on the basis of the published M. tuberculosis inhA gene sequence (1) Site-directed mutagenesis of the M. tuberculosis katG gene. PCR primers were designed to amplify a 2.9-kb EcoRV-KpnI DNA fragment which contained the M. tuberculosis katG gene and to allow cloning into the XbaI and KpnI sites of the mycobacterial vector pMD31 (4, 12, 38) . The sequence of the 5Ј primer utilized in the PCRs (which has a XbaI restriction site tail) was 5Ј-ACTCTAGATGAT TGTTCGATATCCGAC-3Ј, and the 3Ј primer sequence (with a KpnI restriction site tail) was 5Ј-ATGGTACCGCGACCTTCGT-3Ј. M. tuberculosis H37Rv genomic DNA (100 ng) was used as the PCR template. The PCR mixtures were subjected to 35 cycles of amplification (1 min at 94ЊC, 1 min at 55ЊC, 2.5 min at 72ЊC). The expected 2.9-kb product was not detected after PCR amplification under standard reaction conditions. However, when glycerol was added to the reaction mixture to a final concentration of 20%, the full-length 2.9-kb PCR product was amplified. Glycerol has previously been shown to be a cosolvent which can enhance PCR amplification (28) .
The amplified katG products were initially cloned, using the TA cloning system (Invitrogen). The 2.9-kb insert fragment from these clones was digested with XbaI and KpnI and then ligated into the mycobacterial plasmid vector pMD31, using standard protocols. The resulting ligation mixture was then transformed into competent Escherichia coli DH5␣ cells. Recombinant pMD31:katG clones were identified by restriction analyses of purified plasmid DNA. Because of the potential infidelity of PCR amplifications, the katG inserts of several clones were analyzed by SSCP as described above. The clone ZM1 was chosen for further study because this clone had only a single silent mutation within its katG insert.
The Clontech (Palo Alto, Calif.) transformer site-directed mutagenesis kit was used to mutate katG codon 463 in clone ZM1. Briefly, this protocol involved simultaneously annealing to one strand of denatured plasmid DNA two primers: a primer which introduced the desired codon 463 mutation and a primer which eliminated the unique HindIII site in the pMD31 vector. The restriction site mutation allowed the selection of mutated from nonmutated plasmids because the mutated DNA lacked the HindIII restriction site and therefore was resistant to digestion. After standard DNA elongation, ligation, and primary digestion with HindIII, the plasmid pool was transformed into the E. coli strain, BMH 71-18 (mutS), which is defective in mismatched repair. The transformants were pooled, plasmid DNA was prepared, and the isolated DNA was subjected to a second round of HindIII digestion. This pool of plasmid DNA that was enriched for the HindIII restriction site modification was retransformed into BMH 71-18. The presence of codon 463 mutations in the resulting transformants was demonstrated by using the double-stranded sequencing protocols described above.
Preparation and characterization of katG codon 463 mutants. The pMD31: katG clone (ZM1) and three codon 463 mutants were electroporated into the highly INH-resistant, catalase-negative M. smegmatis BH1. Characterization of the M. smegmatis BH1 cells and protocols for the preparation of competent mycobacteria have been described previously (10, 14) . Initially, plasmid DNA (2.5 g) was mixed with 50 l of competent cells, and the mixture was placed on ice for 1 min. The Gene Pulser apparatus (Bio-Rad) was then set to 1,250 V, 25 mF, and 1,000 ⍀. The mixture was transferred to a 0.2-cm-diameter cuvette and pulsed for 10 ms. The cells were subsequently suspended in 1 ml of Middlebrook 7H9 broth containing oleic acid-albumin-glucose complex and 0.05% Tween 80 and incubated at 37ЊC for 3 h. M. smegmatis BH1 transformants were selected on Middlebrook 7H9 agar containing 50 g of kanamycin per ml.
Solid-phase testing and broth MIC analyses were used to evaluate the drug susceptibility of the M. smegmatis BH1 transformants. The solid-phase drug testing consisted of streaking recombinant M. smegmatis BH1 cells on Middlebrook 7H9 plates containing 50 g of kanamycin per ml and either 0, 5, 10, 50, or 100 g of INH per ml. The capacity to restore INH susceptibility was determined by examination of the plates for the presence or absence of cell growth after 24 h of incubation at 37ЊC. The broth MIC measurements were done by using established protocols. Recombinant M. smegmatis BH1 cells (10 3 ) were inoculated into 5 ml of Middlebrook 7H9 broth containing oleic acid-albuminglucose complex, 0.05% Tween 80, 50 g of kanamycin per ml, and 0, 1.6, 3.1, 6.2, 12, 25, 50, 100, or 200 g of INH per ml. Cell growth was evaluated by measuring the A 600 after 48 h of incubation at 37ЊC.
The peroxidase activities of the katG M. smegmatis BH1 recombinants were determined by using a whole-cell assay. Briefly, 2 ϫ 10 8 log-phase cells were centrifuged and resuspended in 1 ml of a 33 mM phosphate-buffered solution (pH 6) containing 4.1 mM 2,4-dichlorophenol, 0.67 mM 4-aminoantipyrine, and 2.9 mM H 2 O 2 . After a 10-min incubation at 37ЊC, the cells were pelleted by centrifugation, and the peroxidase activity was determined by measuring the A 500 (10) . To evaluate the relative levels of katG expression in the transformants, M. smegmatis BH1 sonicates were analyzed by immunoblot assays, using an absorbed polyclonal antibody enriched for reactivity to mycobacterial catalaseperoxidases, as described previously (24) .
RESULTS

SSCP analyses.
Gene fragments containing mutations in the katG and inhA genes were initially identified by using SSCP analyses. For these analyses, each isolate was evaluated with the 11 different katG and 4 different inhA primer sets (19) . PCR products with aberrant SSCP profiles were identified by comparison with the control M. tuberculosis strain, H37Rv, SSCP results. Fig. 1 ). Subsequent nucleotide sequence analyses of clones derived from these PCR products confirmed that these DNA fragments had katG mutations.
Catalase activities and drug resistance levels for clinical isolates. The results of catalase activity assays, drug susceptibility testing, and genetic analyses for the M. tuberculosis clinical isolates are summarized in Characterization of catalase-negative isolates. Several katG gene mutations were detected in the catalase-negative clinical isolates and are summarized in Fig. 2A . Alterations in the katG gene were detected in all 11 catalase-negative, INH-resistant strains examined. Frameshift mutations were identified in three highly resistant strains. Strain 4 had a single base insertion in codon 521 of the katG coding sequence. Small deletions which perturbed the katG reading frame were detected in two other strains-strain 31 has an 8-bp deletion from codon 217 to codon 219, and strain 10 has a 22-bp deletion from codon 289 to codon 296. Missense mutations in the katG gene were identified in the other catalase-negative clinical isolates. The following amino acid substitutions were detected: Thr-262 to Arg (strain 2), Ala-350 to Ser (strain 5), Gly-629 to Ser (strain 9), Ala-717 to Pro (strain 20), His-108 to Gln (strain 28), Asp-63 to Glu (strain 32), Ser-315 to Thr and Arg-463 to Leu (strain 73), and Ile-335 to Thr (strain 74). It is of interest that the Asp-63, His-108, Thr-262, Ser-315, Ala-350, and Gly-629 substitutions occurred in amino acid residues that are conserved among the Mycobacterium intracellulare, E. coli, and Salmonella typhimurium KatG proteins (17, 20, 30) .
Primary sequence comparisons suggest that the mycobacterial KatG protein and the yeast cytochrome c peroxidase are members of the same plant peroxide superfamily (33) . The mycobacterial KatG protein consists of two related domains which have strong similarity to the yeast cytochrome c peroxidase. The putative amino-terminal active-site regions (M. tuberculosis amino acids 94 to 154 and 257 to 276) are 45% identical, and several residues which may be involved in substrate binding or catalysis (Arg-104, His-108, His-270, and His-276) are conserved. Therefore, the structural implications of missense mutations in mycobacterial KatG proteins can be predicted from the known crystal structure of the yeast cytochrome c peroxidase enzyme (9, 33, 34) . On the basis of this predicted structure, the His-108, Thr-262, Ser-315, Ile-335, and Ala-350 residues are located in helical regions of the M. tuberculosis KatG protein. Consequently, mutations at these sites should alter protein structure and affect the activity of the KatG enzyme.
Characterization of catalase-positive isolates. Perturbations in the katG genes of nine catalase-positive isolates were also detected. All of these isolates with katG mutations had a Gto-T transversion which converts Arg-463 to Leu. Since this mutation was detected in a number of catalase-positive isolates, the Arg-to-Leu substitution at codon 463 clearly does not significantly affect the catalase activity of the KatG protein.
Alterations in the inhA operon were identified in two of the catalase-positive and in none of the catalase-negative clinical isolates. Extensive SSCP analyses with three overlapping inhA gene primer sets did not detect any mutations in the inhA coding sequence of these isolates. However, further analyses demonstrated that two strains (strains 8 and 15) had mutations in putative inhA regulatory sequences (Table 1 and Fig. 2B ). The inhA operon consists of two open reading frames: orf1 encodes a 29-kDa protein, and orf2 encodes the 32-kDa InhA protein (1) . In both of these strains, alterations were identified proximal to the translation start codon of orf1. A T-to-G transversion was detected 8 bp upstream of the orf1 initiation codon in strain 15 and adjacent to a predicted ribosome binding site for the inhA operon. A G-to-T transversion was found 24 bp upstream from the translation initiation site of orf1 in strain 8. Similar transversions in putative inhA regulatory sequences have been recently reported in other INH-resistant clinical isolates of M. tuberculosis (16) . Although the relevance of these genetic alterations has yet to be demonstrated, it is possible that mutations in inhA regulatory sequences may cause overexpression of the InhA protein. Increased synthesis of InhA can effectively elevate the levels of the drug target for INH, resulting in a more resistant phenotype (1).
It is interesting to note that neither katG nor inhA genetic alterations were detected in several clinical isolates, including the highly resistant strain 30. Our failure to identify mutations of known genetic markers in these strains suggests that addi- (3, 9, 19) . To evaluate the relative importance of this perturbation, codon 463 of the M. tuberculosis katG H37Rv gene was changed from an Arg to a Leu by site-directed mutagenesis. Initially, the capacity of this codon 463 mutant to restore INH susceptibility to a catalase-negative, INH-resistant M. smegmatis strain, BH1, was assessed by using solid-phase assays. M. smegmatis BH1 cells were transformed with the mycobacterial plasmid vector pMD31 containing the M. tuberculosis katG gene (Arg-463) and with pMD31 containing the katG codon 463 mutant (Leu-463). M. smegmatis BH1 cells transformed with the vector pMD31 and with pMD31 containing an irrelevant mycobacterial gene fragment served as controls. As seen in Fig. 3 , all the transformants grow on Middlebrook 7H9 agar containing kanamycin. However, when these recombinants are streaked onto solid medium containing kanamycin and 100 g of INH per ml, only the control M. smegmatis BH1 transformants proliferate (Fig. 3, rows 1 and 4) . The absence of growth of the M. smegmatis BH1 transformants in rows 2 and 3 suggests that expression of either the wild-type or the codon 463 mutant M. tuberculosis KatG restores INH susceptibility to M. smegmatis BH1 cells.
The M. smegmatis BH1 transformants were also evaluated for INH susceptibility by using standard broth MIC assays. Consistent with the solid-phase results, the MICs for the control strains exceeded 200 g/ml of INH, while the MICs for M. smegmatis BH1 transformants expressing the M. tuberculosis KatG or the codon 463 mutant protein were 10 g/ml. Therefore, expression of either the wild-type or the mutant katG gene enhanced INH susceptibility in M. smegmatis BH1 cells by at least 20-fold.
To assess the relative enzymatic activities of the wild-type and mutant KatG proteins, the levels of katG expression and the peroxidase activities of the M. smegmatis BH1 transformants were determined. Immunoblot assays using a polyclonal antibody enriched for mycobacterial catalase reactivity demonstrated that the levels of expression of wild-type and mutant KatG proteins in several M. smegmatis BH1 transformants were essentially equivalent. Moreover, no difference in the peroxidase activities of strains expressing wild-type or mutant proteins was detected. However, the peroxidase activities measured in M. smegmatis BH1 cells expressing either the wild-type or mutant KatG proteins were fivefold higher than for the vector control. These results suggest that the codon 463 Argto-Leu substitution does not significantly alter the level of expression of katG or the peroxidase activity of the M. tuberculosis catalase-peroxidase.
DISCUSSION
Although INH has been a key component of tuberculosis chemotherapeutic regimens for several decades, the mechanism of action of this highly specific and reactive drug remains obscure. Recent reports have suggested that INH or a derivative of INH may act by blocking the synthesis of mycolic acids in drug-susceptible mycobacteria and that this inhibition involves the inhA gene product, an enoyl acyl reductase in the mycolic acid biosynthetic pathway (1, 6) . Furthermore, the toxicity of the drug seems to be potentiated by its interactions with the mycobacterial catalase-peroxidase (27, 31) It is of interest that neither katG nor inhA gene mutations were detected in four of the isolates evaluated in these experiments. Heym and coworkers have also reported that a number of clinical isolates had no mutations in these genetic markers of INH resistance (9, 11) . Since several of the previously described resistant strains that have wild-type katG and inhA genes are catalase negative, the expression of katG in some strains may be impaired by an undefined regulatory defect. Consistent with this possibility, Rosner and colleagues have shown that E. coli oxyR mutants (the oxyR regulon controls katG expression in E. coli) have altered susceptibility to INH (22, 23 (9, 33, 34) . Although these predictions strongly suggest that particular mutations are linked to drug resistance, the absence of a consistent genetic background among clinical isolates prevents an absolute delineation of the association between specific changes in the katG gene and resistance to INH in these strains. To circumvent this problem, resistant mutants of a reference strain can be isolated and the effect of relevant mutations can be characterized. Using this strategy, we have recently shown in an INH-resistant mutant of H37Rv that substitution of a Pro for a Thr in KatG residue 275 eliminates catalase activity and decreases susceptibility to INH (24) . Alternatively, as shown in the codon 463 studies, the effects of mutational events on KatG function can be evaluated by using site-directed mutagenesis. Studies using specific mutagenesis protocols to more definitively identify critical KatG residues are currently in progress.
The most frequent and intriguing amino acid substitution identified in clinical isolates of M. tuberculosis is the codon 463 Arg-to-Leu replacement. Some evidence suggests that this substitution may be relevant to drug resistance. Our group and others have detected this change in 20 to 45% of INH-resistant clinical isolates (3, 9, 19) . The Arg residue is found only in position 463 of the wild-type M. tuberculosis protein, while the more INH-resistant M. intracellulare and Bacillus stearothermophilus strains have a Leu at an equivalent residue (18, 20) . Moreover, the only katG gene alteration detected in one resistant mutant of H37Rv resulted in the same codon 463 Argto-Leu change (24) . In contrast, the site-directed mutagenesis experiments presented in this study demonstrated that the Arg-to-Leu change had no significant effect on the peroxidase activity or the drug susceptibility of recombinant M. smegmatis BH1 cells. Furthermore, we have detected this substitution in 5 of 24 INH-susceptible M. tuberculosis clinical isolates (25) . Whether this codon 463 substitution is a frequent polymorphic event or is relevant to drug resistance needs further clarification. Repeating the site-directed mutagenesis studies in a slowly growing katG-deficient mycobacterial strain may be required to more clearly define the effect of this mutation.
In summary, we have detected multiple katG and inhA gene mutations in clinical isolates that may be associated with INH resistance. We initially speculated that rapid diagnostic tests for identifying INH-resistant bacilli could be developed on the basis of the detection of these alterations in drug target genes.
The consistency of rpoB mutations in rifampin-resistant isolates suggests that rapid molecular tests for identifying reduced susceptibility to rifampin will be feasible (29) . However, in our studies and other recent reports, at least 20 katG mutations (encompassing the entire katG gene) and 6 inhA alterations have been identified (3, 9, 16, 19) . Because of the number of perturbations identified and the variable locations of the katG alterations, it is unlikely that useful amplification-based diagnostic methods will be available in the near future for rapidly detecting INH-resistant clinical isolates. Given this circumstance, the continued development of alternative diagnostic approaches for identifying drug-resistant mycobacteria, such as mycobacteriophage reporter assays, is clearly warranted (13) .
